Prokinetics and Body Surface Gastric Mapping in Dyspeptic Patients: Baseline and Treatment Effects
Launched by UNIVERSITY OF AUCKLAND, NEW ZEALAND · Feb 25, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain medications, called prokinetics and symptom modulators, can help patients with stomach disorders known as gastroparesis and functional dyspepsia. These conditions can cause uncomfortable symptoms like feeling full quickly, nausea, and stomach pain. The researchers will use a new, non-invasive tool called Body Surface Gastric Mapping (BSGM) to examine how the stomach works before and after treatment. By doing this, they hope to learn more about how these medications affect stomach function and find ways to personalize treatments based on each person's specific needs.
To participate in this study, you need to be at least 18 years old and have been diagnosed with either gastroparesis or functional dyspepsia. You also need to be receiving a type of medication for these conditions. Participants will undergo two BSGM recordings: one before starting the medication and another during treatment. It’s important to note that individuals with certain medical histories, such as previous stomach surgeries or skin allergies, may not be eligible. Overall, this trial aims to improve understanding and treatment of these common stomach issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients 18 years of age and older
- • Diagnosis of gastroparesis and/or functional dyspepsia
- • Being prescribed a prokinetic agent or symptom modulator for their clinical care
- • Able to undergo BSGM recording both before and during treatment
- • Able to give informed consent for undergoing a baseline BSGM recording and an additional recording while on treatment
- Exclusion Criteria:
- • Under 18 years of age
- • Prior surgery on esophagus, stomach (appendectomy and cholecystectomy are allowed)
- • History of skin allergies or a history of extreme sensitivity to cosmetics or lotions
- • Pregnant women
- • No vulnerable groups such as prisoners, individuals with known cognitive impairment, or institutionalized individuals be involved
About University Of Auckland, New Zealand
The University of Auckland, located in New Zealand, is a leading research institution committed to advancing knowledge and improving health outcomes through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive expertise in medical research, public health, and pharmacology to conduct rigorous studies that address pressing health challenges. The institution is dedicated to ethical research practices and aims to translate findings into meaningful clinical applications, ultimately enhancing patient care and contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Sydney, New South Wales, Australia
Auckland, , New Zealand
Patients applied
Trial Officials
Henry Parkman, MD
Principal Investigator
Temple University
Vincent Ho, MBBS, FRACP, FACP, PhD
Principal Investigator
University of Western Sydney
Charlotte Daker, MD
Principal Investigator
University of Auckland, New Zealand
Greg O'Grady, MD, PhD
Principal Investigator
University of Auckland, New Zealand
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported